• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Viewpoints

Chagas Disease in Colombia: An opportunity to lead the way towards change

30 Apr 2015

Rafael VilasanjuanEric StobbaertsViewpoint by

Rafael Vilasanjuan, ISGlobal and Eric Stobbaerts, DNDi Latin America, Members of the Global Chagas Disease Coalition

During the month that celebrates International Chagas Disease day, Colombia, via its Ministry of Health has confirmed its commitment to the disease, a reason for optimism for the entire region. Aware of the difficulty of access to diagnosis and treatment (less than 1,000 patients treated), an action plan has been proposed to tackle Chagas Disease under the leadership of the Ministry of Health and Social Protection. A model project supported by DNDi and capable of being implemented in other locations arose as an example and brings hope not only to the 437 thousand infected persons and roughly 4.8 million people at risk of being infected in the country, but also for other affected countries.

Chagas Disease is a silent and silenced public health crisis. A disease caused by the Trypanosoma cruzi parasite that lodges in the different body tissues and, in 30% of chronic patients, leads to irreversible heart lesions, while in another 10% it causes neurological and digestive tract lesions. Close to six million people throughout the world are infected and every year the toll amounts to 10,000  lives. It is time for a change, treatment is possible and there is no reason for staying silent on this disease.

There are currently two medications available, benznidazol and nifurtimox. The former, the first treatment option, is produced in Argentina and Brazil, yet it is necessary to facilitate access to them and to ensure a strong political commitment by the affected countries in order to increase the treatment programmes. There is an urgent need to save lives, improve the quality of life of infected persons and avoid the related costs that affect individual patients, families, caretakers, doctors and health systems.

In addition to the example provided by Colombia, there are several encouraging activities in the region, such as  the project that Fundación Mundo Sano is undertaking jointly with the authorities in the municipality of La Plata, Argentina, the full-time patient care platforms in Bolivia, headed by Ceades and ISGlobal, as well as the multiple projects under the guidance of Doctors Without Borders/MSF in several countries.

Treatment for Chagas Disease patients is the right of affected persons, a public health issue, but if all of this were not sufficient, it is also an investment that saves funds, improves the quality of life and reduces productivity losses related to the disease. It is no doubt a wise decision and an outstanding commitment. Only by uniting efforts to fight Chagas Disease, will we be able to achieve the goal of relieving human suffering caused by this disease.

This is the dream of the Global Chagas Coalition, an open, ambitious and cooperative alliance that by means of joint efforts and an interchange of expertise and experience,  enables the  mobilization of abilities and resources in order to increase access to diagnosis and treatment, and to encourage investigations and development of effective solutions. The Coalition invites all those with expertise and commitment to participate in this alliance.

We at the Chagas Coalition hope that the Colombian example will inspire other countries in the region to consolidate their procedures to make a real change to the disease’s panorama. Latin American countries have a key role in taking the lead in this path.

[Español] [Português]

Rafael Vilasanjuan, IS Global and Eric Stobbaerts, DNDi Latin America

Chagas disease

Read, watch, share

Loading...
Statements
8 May 2025

DNDi’s briefing note for 78th World Health Assembly

Marco Krieger
News
30 Apr 2025

Message on the passing of Dr Marco Aurélio Krieger, Vice-President of Production and Innovation in Health, Fiocruz

Screening activities in village in Guinea
News
25 Apr 2025

Statements from Dr Luis Pizarro and Daisuke Imoto about the Hideyo Noguchi Africa Prize awarded to DNDi

Two man outside of a hospital talking with a nurse
Press releases
24 Apr 2025

Liverpool clinical trial aims to advance life-changing treatment for a deadly parasitic disease

Woman walking in a laboratory
Press releases
23 Apr 2025

DNDi welcomes GHIT support for new project with three Japanese universities to find drug candidates for Chagas disease

Stories
16 Apr 2025

Drug discovery explained: Chagas – How to prove treatments work?

Statements
16 Apr 2025

Statement from the Drugs for Neglected Diseases initiative (DNDi) on the conclusion of WHO Pandemic Agreement negotiations

Press releases
15 Apr 2025

New treatment for cryptococcal meningitis enters Phase II trial as global HIV funding cuts threaten to cause a massive increase in advanced HIV disease

VIEW ALL

Help neglected patients

To date, we have delivered thirteen new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
Linkedin-in Instagram Twitter Facebook-f Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License